Hot Biotech Stocks To Own For 2019

tags:ALNY,BIIB,ARQL,AMGN,

News stories about NewLink Genetics (NASDAQ:NLNK) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. NewLink Genetics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.8843226822969 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of NewLink Genetics traded down $0.06, reaching $5.10, during trading hours on Friday, according to MarketBeat. The company had a trading volume of 1,768,300 shares, compared to its average volume of 952,710. The company has a market capitalization of $196.23 million, a PE ratio of -2.22 and a beta of 1.25. NewLink Genetics has a 12-month low of $3.75 and a 12-month high of $19.30.

Hot Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Keith Speights]

  It's not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum's market cap is less than $350 million while Alnylam's market cap is close to $10 billion.

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  So, which biotech stocks should you consider buying in June? That's a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

• [By Max Byerly]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

• [By Cory Renauer]

  If approved, Tegsedi will run directly into competition with Alnylam's (NASDAQ:ALNY) recently approved treatment for the limited population of ATTR patients, Onpattro. Inotersen and Onpattro haven't been tested in a head-to-head study, but most analysts expect Alnylam's drug to gain a much larger share of the limited space than Akcea's.

Hot Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Cory Renauer]

  Biogen Inc. (NASDAQ:BIIB) and Gilead Sciences, Inc. (NASDAQ:GILD) were two of biotech's best-performing stocks in years past, but investors are a lot more worried about where they're going right now. Gilead Sciences has a new management team and a new focus on treating cancer. Now that competitors have diminished Biogen's dominance in the multiple sclerosis space, the company's taking bold steps as well.

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.33 million shares from the previous 3.86 million. The stock recently traded at $306.68 within a 52-week range of $249.17 to $370.57.

• [By Chris Lange]

  Biogen Inc.’s (NASDAQ: BIIB) second-quarter report is scheduled for Tuesday before the markets open. The consensus estimates are $5.24 in earnings per share (EPS) on $3.26 billion in revenue. The shares ended the week trading at $357.56. The consensus price target is $367.08, and the 52-week trading range is $249.17 to $370.57.

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 4.00 million shares from the previous 3.91 million. The stock recently traded at $346.90, within a 52-week range of $249.17 to $388.67.

• [By Chris Lange]

  Nightstar Therapeutics PLC (NASDAQ: NITE) shares exploded early on Monday after it was announced that the firm would be acquired by Biogen Inc. (NASDAQ: BIIB). The transaction is expected to close by mid-year 2019.

• [By Dan Caplinger]

  Wall Street continued its downward streak on Monday, with the Dow Jones Industrial Average falling more than 100 points. Most major benchmarks fell more modestly, with a few actually poking into positive territory on the day. Trade-sensitive stocks were among the weakest as investors focused on uncertainty related to tariff disputes between the U.S. and China. But for some other companies, bad news of a different sort was responsible for the drops in their shares. Biogen (NASDAQ:BIIB), Baytex Energy (NYSE:BTE), and Catalyst Biosciences (NASDAQ:CBIO) were among the worst performers on the day. Here's why they did so poorly.

Hot Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Max Byerly]

  Get a free copy of the Zacks research report on ArQule (ARQL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Cory Renauer]

  What's behind these dramatic gains? Read on to find out.

  Company Gain in H1 2018 Market Cap Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion ArQule, Inc. (NASDAQ:ARQL) 235% $482 million Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

  Data source: YCharts.

• [By Motley Fool Transcribers]

  Arqule Inc  (NASDAQ:ARQL)Q4 2018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on ArQule (ARQL)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Money Morning Staff Reports]

  But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we'll show you a small-cap stock with great profit potential in its future…

  Penny Stock Current Share Price Law Month's Gain  Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85% Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40% Vivis Inc. (Nasdaq: VVUS) $0.77 150.41% Adomani Inc. (Nasdaq: ADOM) $1.49 137.68% NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88% Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06% Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12% ArQule Inc. (Nasdaq: ARQL) $4.88 90.74% LiqTech International Inc. (NYSE: LIQT) $0.66 85.60% Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

  While last month's gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Hot Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Cory Renauer]

  Sanofi took the assessment and started engaging end payers to see if any would offer easy reimbursement for a lower net price that reflects ICER's assessment, and the industry listened. As of July 1, the partners will cut the net price of Praluent in return for straightforward access for around 25 million Americans covered by the Express Scripts (NASDAQ:ESRX) national formulary. The pharmacy benefits manager, and will also remove formulary access for its main competitor, Amgen's (NASDAQ:AMGN) Repatha.

• [By Todd Campbell]

  Neulasta has been one of Amgen's (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan's (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta's revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen's market share? Read on to find out what's at stake for these companies and their investors.

• [By Chris Lange]

  Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 10.24 million shares from the previous level of 10.63 million. Shares were last seen trading at $206.00, in a 52-week trading range of $163.31 to $210.19.

• [By Cory Renauer]

  With Johnson & Johnson picking up the tab for ARO-HPV, Arrowhead can direct more resources toward candidates it still owns outright. Although Arrowhead has several preclinical stage candidates that could begin their first human studies soon, just two other candidates are in their first clinical trials right now, a wholly owned candidate for the treatment alpha-1 antitrypsin deficiency (AATD), and a cardiology drug partnered with Amgen (NASDAQ:AMGN).  

• [By Stephan Byrd]

  Marco Investment Management LLC raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,601 shares of the medical research company’s stock after buying an additional 5,265 shares during the period. Amgen comprises approximately 3.4% of Marco Investment Management LLC’s portfolio, making the stock its 3rd largest position. Marco Investment Management LLC’s holdings in Amgen were worth $21,893,000 as of its most recent SEC filing.

• [By Todd Campbell]

  When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers Amgen Inc. (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Sanofi SA (NYSE:SNY) in the lurch.